#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Primary aldosteronism


Authors: A. Tokárčiková
Authors‘ workplace: IV. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura Košice, Slovenská republika, prednosta prof. MUDr. Ivan Tkáč, Ph. D.
Published in: Vnitř Lék 2007; 53(9): 1000-1002
Category: Review

Práca bola prednesená na XIII. memoriáli prof. MUDr. Františka Póra 25. apríla 2006 v Košiciach.

Overview

Primary aldosteronism is caused by autonomous overproduction of aldosteron in the adrenocortical cells of zona glomerulosa. It is the most frequent form of endocrine hypertension. The morphologic base of this disorder are tumorous, or hyperplastic changes of the adrenal gland. Syndrome is divided into more well-defined pathogenetic forms. Therapy that we use is conservative, or surgical. Success of treatment depends on the correct diagnosis of pathogenetic form and on the duration of hypertension.

Key words:
primary aldosteronism - pathogenetic forms - drug therapy - adrenalectomy


Sources

1. Widimský J jr, Zelinka T. Endokrinní hypertenze. In: Widimský J et al. Hypertenze. Praha: Triton 2004: 518-540.

2. William FY jr. Adrenal Cortex Hypertension. In: Oparil S, Weber MA. Hypertension. Philadephia: Elsevier Saunders 2005: 792-806.

3. Tokárčiková A. Endokrinne podmienené hypertenzie. In: Jonáš P et al. Artériová hypertenzia v praxi. Košice: Maxdorf 2001: 212-225.

4. Balažovjech I. Hypertenzie podmienené ochorením nadobličky. In: Balažovjech I. Artériová hypertenzia. Martin: Osveta 1999: 322-331.

5. Edwards ChRW. Primary Mineralocorticoid Excess Syndromes. In: DeGroot LJ, Jameson JL et al. Endocrinology. Philadelphia: WB Saunders Company 2001: 1820-1844.

6. Janota T, Widimský J, Král J et al. Structural heart changes in primary hyperaldosteronism and their reversibility. Eur Heart J 1998; 19: 423.

7. Calhoun DA. Resistant Hypertension. In: Oparil S, Weber MA. Hypertension. Philadelphia: Elsevier Saunders 2005: 616-623.

8. Kreze A sr. Hyperfunkcia kôry nadobličiek. In: Kreze A et al. Všeobecná a klinická endokrinológia. Bratislava: AEP 2004: 373-392.

9. Fardella CE, Mosso L, Gómez-Sánchez C et al. Primary hyperaldosteronism in essential hypertension: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.

10. Ganguly A. Primary aldosteronism. New Engl J Med 1998; 339: 1828-1834.

11. Vallotton MB. Primary aldosteronism. Part I. Diagnosis of primary aldosteronism. Clinical Endocrinology 1996; 45: 47-52.

12. Streeten DHP, Anderson GH jr. Aldosterone disorders. In: Moore WT, Eastman RC. Diagnostic endocrinology. St. Louis: Mosby 1996: 283-298.

13. Puccini M, Iacconi P et al. Conn Syndrome: 14 Year´s Experience from Two European Centres. Eur J Surg 1998; 164: 811-817.

14. Dluhy RG, Lawrence JE, Williams GH. Endocrine Hypertension. In: Larsen PR, Kronenberg HM, Melmed S et al. Philadelphia: WB Saunders 2003: 552-585.

15. Proye ChAG, Mulliez EAR et al. Essential hypertension: First reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 1998; 124: 1128-1133.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 9

2007 Issue 9

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#